Inhibitors of Mitochondrial Human Carbonic Anhydrases VA and VB as a Therapeutic Strategy against Paclitaxel-Induced Neuropathic Pain in Mice

• Published in: International journal of molecular sciences 2022-06, Vol.23 (11), p.6229
• Main Authors: Micheli, Laura, Testai, Lara, Angeli, Andrea, Carrino, Donatello, Pacini, Alessandra, Margiotta, Francesco, Flori, Lorenzo, Supuran, Claudiu T, Calderone, Vincenzo, Ghelardini, Carla, Di Cesare Mannelli, Lorenzo
• Format: Article
• Language: English
• Subjects: Acetazolamide; Acidosis; Apoptosis; CA VA and VB; Calcium ions; carbonic anhydrase; Cell activation; Central nervous system; Chemotherapy; Citrate synthase; Deregulation; Drug development; Drug dosages; Enzymes; Experiments; Glial cells; Homeostasis; Isoforms; Lactic acid; Membrane potential; Mitochondria; Mitochondrial DNA; Neuronal-glial interactions; neuropathic pain; Neurotoxicity; Oxidative stress; Paclitaxel; Pain; Pain management; Pathology; Phosphorylation; Physiology; Quality of life; Reactive oxygen species; Rheumatoid arthritis; Selenides; Taxus brevifolia; Therapeutic targets
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23116229

Neuropathy development is a major dose-limiting side effect of anticancer treatments that significantly reduces patient's quality of life. The inadequate pharmacological approaches for neuropathic pain management warrant the identification of novel therapeutic targets. Mitochondrial dysfunctions that lead to reactive oxygen species (ROS) increase, cytosolic Ca imbalance, and lactate acidosis are implicated in neuropathic pain pathogenesis. It has been observed that in these deregulations, a pivotal role is played by the mitochondrial carbonic anhydrases (CA) VA and VB isoforms. Hence, preclinical studies should be conducted to assess the efficacy of two novel selenides bearing benzenesulfonamide moieties, named and , and able to inhibit CA VA and VB against paclitaxel-induced neurotoxicity in mice. Acute treatment with and (30-100 mg/kg, per os - p.o.) determined a dose-dependent and long-lasting anti-hyperalgesic effect in the Cold plate test. Further, repeated daily treatment for 15 days with 100 mg/kg of both compounds (starting the first day of paclitaxel injection) significantly prevented neuropathic pain development without the onset of tolerance to the anti-hyperalgesic effect. In both experiments, acetazolamide (AAZ, 100 mg/kg, p.o.) used as the reference drug was partially active. Moreover, ex vivo analysis demonstrated the efficacy of and repeated treatments in reducing the maladaptive plasticity that occurs to glia cells in the lumbar portion of the spinal cord and in improving mitochondrial functions in the brain and spinal cord that were strongly impaired by paclitaxel-repeated treatment. In this regard, and ameliorated the metabolic activity, as observed by the increase in citrate synthase activity, and preserved an optimal mitochondrial membrane potential (ΔΨ) value, which appeared depolarized in brains from paclitaxel-treated animals. In conclusion, and have therapeutic and protective effects against paclitaxel-induced neuropathy without tolerance development. Moreover, and reduced glial cell activation and mitochondrial dysfunction in the central nervous system, being a promising candidate for the management of neuropathic pain and neurotoxicity evoked by chemotherapeutic drugs.